Cargando…

Use of the VerifyNow point of care assay to assess the pharmacodynamic effects of loading and maintenance dose regimens of prasugrel and ticagrelor

Prasugrel and ticagrelor are potent oral platelet P2Y(12) inhibitors and are recommended over clopidogrel in patients with acute coronary syndrome (ACS). Oral platelet P2Y(12) inhibitors are characterized by varying degrees of pharmacodynamic response profiles as assessed by a variety of commerciall...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angiolillo, Dominick J., Been, Latonya, Rubinstein, Marc, Martin, Michael, Rollini, Fabiana, Franchi, Francesco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049919/ https://www.ncbi.nlm.nih.gov/pubmed/33582955 http://dx.doi.org/10.1007/s11239-021-02386-7

Ejemplares similares

Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-Function Genotypes: Results of a Randomized Pharmacodynamic Study in a Feasibility Investigation of Rapid Genetic Testing
por: Franchi, Francesco, et al.
Publicado: (2020)

Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y(12) Assay in Patients With Coronary Artery Disease
por: Koga, Seiji, et al.
Publicado: (2020)

Periprocedural Variability of Platelet Functions in Carotid Artery Stenting: An Analysis Using VerifyNow
por: Yoshimura, Masataka, et al.
Publicado: (2021)

Application of Auxiliary VerifyNow Point-of-Care Assays to Assess the Pharmacodynamics of RUC-4, a Novel αIIbβ3 Receptor Antagonist
por: Bentur, Ohad S., et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic profiles of a novel phospholipid-aspirin complex liquid formulation and low dose enteric-coated aspirin: results from a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2022)

Comparison of VerifyNow, thromboelastography, and PL-12 in patients with minor ischemic stroke or transient ischemic attack
por: Ma, Lin, et al.
Publicado: (2021)

Clopidogrel non-responsiveness in patients undergoing percutaneous coronary intervention using the VerifyNow test: frequency and predictors
por: Yaseen, Israa Fadhil, et al.
Publicado: (2019)

Impact of Routine Platelet Reactivity Testing with VerifyNow Assay on Antiplatelet Choice After Percutaneous Coronary Intervention
por: Mshelbwala, Fakilahyel S, et al.
Publicado: (2020)

Blood loss after coronary artery bypass by aspirin responsiveness assessed with preoperative VerifyNow aspirin testing
por: Willemsen, Laura M., et al.
Publicado: (2021)

Impact of Diabetes Mellitus on the Pharmacodynamic Effects of Ticagrelor Versus Clopidogrel in Troponin‐Negative Acute Coronary Syndrome Patients Undergoing Ad Hoc Percutaneous Coronary Intervention
por: Sweeny, Joseph M., et al.
Publicado: (2017)

Different Influences of Hematocrit on the Results of Two Point-Of-Care Platelet Function Tests, the VerifyNow Assay and Multiple Electrode Platelet Aggregometry
por: Kim, Yun Gi, et al.
Publicado: (2014)

Investigation of the interaction between proton pump inhibitors and clopidogrel using VerifyNow P2Y12 assay
por: Lin, Sheng-Feng, et al.
Publicado: (2020)

Performance comparison of aspirin assay between Anysis and VerifyNow: Assessment of therapeutic platelet inhibition in patients with cardiac diseases
por: Piao, Jinxiang, et al.
Publicado: (2021)

Long‐Term Ticagrelor Versus Prasugrel Pharmacodynamics in Patients With ST‐Segment–Elevation Myocardial Infarction
por: Cassese, Salvatore, et al.
Publicado: (2020)

The optimal threshold of high post-treatment platelet reactivity could be defined by a point-of-care VerifyNow P2Y12 assay
por: Jeong, Young-Hoon, et al.
Publicado: (2008)

Point of Care Tests VerifyNow P2Y12 and INNOVANCE PFA P2Y Compared to Light Transmittance Aggregometry After Fibrinolysis
por: Roule, Vincent, et al.
Publicado: (2018)

Change of Platelet Reactivity to Antiplatelet Therapy after Stenting Procedure for Cerebral Artery Stenosis: VerifyNow Antiplatelet Assay before and after Stenting
por: Lee, Deok Hee, et al.
Publicado: (2012)

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

Effects of D-allulose on glucose tolerance and insulin response to a standard oral sucrose load: results of a prospective, randomized, crossover study
por: Franchi, Francesco, et al.
Publicado: (2021)

Pharmacodynamic Effects of Vorapaxar in Patients With and Without Diabetes Mellitus: Results of the OPTIMUS-5 Study
por: Franchi, Francesco, et al.
Publicado: (2019)

When Less Becomes More: Insights on the Pharmacodynamic Effects of Aspirin Withdrawal in Patients With Potent Platelet P2Y(12) Inhibition Induced by Ticagrelor
por: Capodanno, Davide, et al.
Publicado: (2020)

Unmet needs in the management of acute myocardial infarction: role of novel protease-activated receptor-1 antagonist vorapaxar
por: Cho, Jung Rae, et al.
Publicado: (2014)

Clinical implementation of rapid CYP2C19 genotyping to guide antiplatelet therapy after percutaneous coronary intervention
por: Cavallari, Larisa H., et al.
Publicado: (2018)

Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
por: Alexopoulos, Dimitrios, et al.
Publicado: (2013)

A randomised trial of the pharmacodynamic and pharmacokinetic effects of ticagrelor compared with clopidogrel in Hispanic patients with stable coronary artery disease
por: Price, Matthew J., et al.
Publicado: (2014)

Ticagrelor and prasugrel are independent predictors of improved long‐term survival in ACS patients
por: Gager, Gloria M., et al.
Publicado: (2020)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

Pharmacokinetic–pharmacodynamic modelling of platelet response to ticagrelor in stable coronary artery disease and prior myocardial infarction patients
por: Åstrand, Magnus, et al.
Publicado: (2018)

Pharmacodynamic Effects of Vorapaxar in Prior Myocardial Infarction Patients Treated With Potent Oral P2Y(12) Receptor Inhibitors With and Without Aspirin: Results of the VORA‐PRATIC Study
por: Franchi, Francesco, et al.
Publicado: (2020)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Evaluation of the Pharmacokinetics and Pharmacodynamics of Prasugrel in Japanese Elderly Subjects
por: Hasunuma, Tomoko, et al.
Publicado: (2017)

Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
por: Alexopoulos, Dimitrios, et al.
Publicado: (2015)

Incidence, predictors, and prognosis of premature discontinuation or switch of prasugrel or ticagrelor: the ATLANTIS - SWITCH study
por: Winter, Max-Paul, et al.
Publicado: (2019)

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Ticagrelor or prasugrel in patients with acute coronary syndrome with off-hour versus on-hour presentation: a subgroup analysis of the ISAR-REACT 5 trial
por: Behnes, Michael, et al.
Publicado: (2022)

Comparison of VerifyNow-P2Y(12 )test and Flow Cytometry for monitoring individual platelet response to clopidogrel. What is the cut-off value for identifying patients who are low responders to clopidogrel therapy?
por: Godino, Cosmo, et al.
Publicado: (2009)

Real-world comparison of clopidogrel, prasugrel and ticagrelor in patients undergoing primary percutaneous coronary intervention
por: Krishnamurthy, Arvindra, et al.
Publicado: (2019)

No Differences in Gastrointestinal Bleeding Risk among Clopidogrel-, Ticagrelor-, or Prasugrel-Based Dual Antiplatelet Therapy
por: Laredo, Viviana, et al.
Publicado: (2020)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Real‐World Evidence on Disparities on the Initiation of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
por: Yildirim, Mustafa, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_38q68l6bq3pbpcevt495tbp9pl